Wait, don't miss out on the latest GovCon industry news!

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings

*By clicking "Join us now" you agree to receive email, promotions and general messages from GovCon Wire, In addition, you also agree to GovCon Wire Privacy Policy and Terms & Conditions.

X Remind me Later

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

Jeff Brody

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.

HHS said Wednesday its Biomedical Advanced Research and Development Authority will provide technical services and funds to help Paratek carry out research and manuacturing efforts for the Nuzyra drug, generically known as omadacycline.

The contract marks the department's first award under Project BioShield, which incentivizes pharmaceutical companies to produce medical products meant to help the government counter biological, chemical, radiological and nuclear threats.

The Food and Drug Administration approved oral and intravenous forms of Nuzyra for adults who suffer from community-acquired pneumonia and acute skin infection.

Boston-based Paratek aims to secure emergency use authorization for antibiotic treatment of anthrax lung infections. BARDA will buy an initial supply if the company obtains FDA approval for expanded use of the drug.

GovCon Wire Logo

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings about Contract Awards

Related Articles